Excerpt: Xinyao (Criss) Wang, a HK/China healthcare analyst writing on SmartKarma is bullish for CanSino, pointing to the demand/supply mismatch for blood products intensifying. “There’s little way to increase production capacity in short time,” says Wang.
Nick Herbert • (Opens in a new window) ⧉
Are you a Professional Journalist?
The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.
